Compare PBT & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | PHAR |
|---|---|---|
| Founded | 1980 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 885.7M |
| IPO Year | N/A | 2020 |
| Metric | PBT | PHAR |
|---|---|---|
| Price | $29.00 | $12.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 160.3K | 9.3K |
| Earning Date | 03-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $57.37 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.70 | $9.54 |
| 52 Week High | $32.25 | $21.34 |
| Indicator | PBT | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 39.90 |
| Support Level | $27.67 | $11.84 |
| Resistance Level | $32.25 | $13.61 |
| Average True Range (ATR) | 1.66 | 0.47 |
| MACD | -0.30 | 0.08 |
| Stochastic Oscillator | 43.96 | 29.83 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.